| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-10-22 | Weiss Lawrence T SVP, Chief Legal Officer | Purchase | +10,000 | +11.96%93,597 | $11.81 | $118,100 | View SEC filing | |
| 2025-10-14 | Trowbridge Stephen A EVP and CFO | Purchase | +890 | +0.35%256,629 | $11.16 | $9,932 | View SEC filing | |
| 2025-10-09 | Clemmer James C President and CEO | Purchase | +10,000 | +1.15%882,529 | $11.15 | $111,500 | View SEC filing | |
| 2025-01-17 | Nighan Warren JR SVP Quality and Regulatory | Sale | -4,060 | -8.85%41,817 | $12.31 | $49,979 | View SEC filing | |
| 2024-10-10 | Nighan Warren JR SVP Quality and Regulatory | Purchase | +868 | +1.93%45,877 | $6.09 | $5,285 | View SEC filing | |
| 2024-10-08 | Trowbridge Stephen A EVP and CFO | Purchase | +1,700 | +0.99%172,711 | $5.86 | $9,962 | View SEC filing | |
| 2024-10-08 | Clemmer James C President and CEO | Purchase | +20,000 | +3.02%681,582 | $6.03 | $120,600 | View SEC filing | |
| 2024-04-08 | Clemmer James C President and CEO | Purchase | +10,000 | +1.89%539,066 | $6.70 | $67,000 | View SEC filing | |
| 2023-02-01 | Helsel Dave SVP Global Operations and R&D | Sale | -4,633 | -19.45%19,189 | $12.95 | $59,997 | View SEC filing | |
| 2022-10-12 | Trowbridge Stephen A EVP and CFO | Purchase | +1,083 | +1.22%89,581 | $13.82 | $14,967 | View SEC filing | |
| 2022-10-11 | Clemmer James C President and CEO | Purchase | +10,000 | +2.27%450,407 | $15.00 | $150,000 | View SEC filing | |
| 2022-08-01 | Helsel Dave SVP Global Operations and R&D | Sale | -5,000 | -17.35%23,822 | $22.44 | $112,200 | View SEC filing | |
| 2022-05-02 | Helsel Dave SVP Global Operations and R&D | Sale | -3,513 | -13.31%22,874 | $22.44 | $78,832 | View SEC filing | |
| 2022-04-13 | JOHNSON WESLEY Director | Sale | -7,500 | -7.54%79,704 | $23.05 | $172,838 | View SEC filing | |
| 2022-01-12 | Trowbridge Stephen A EVP and CFO | Purchase | +1,000 | +1.33%76,081 | $22.64 | $22,640 | View SEC filing | |
| 2022-01-12 | Clemmer James C President and CEO | Purchase | +10,000 | +2.63%390,764 | $22.84 | $228,400 | View SEC filing | |
| 2021-10-21 | Helsel Dave SVP Global Operations and R&D | Sale | -3,494 | -11.69%26,387 | $27.97 | $97,727 | View SEC filing | |
| 2021-10-18 | Centea Scott Sr. VP/GM, Global VIT | Sale | -12,000 | -20.60%46,244 | $27.92 | $335,040 | View SEC filing | |
| 2021-10-06 | Campbell Chad Thomas SVP/GM, Vascular Access | Sale | -10,748 | -25.30%31,741 | $27.15 | $291,808 | View SEC filing | |
| 2021-04-15 | Helsel Dave SVP Global Operations and R&D | Sale | -3,500 | -15.48%19,115 | $23.93 | $83,755 | View SEC filing | |
| 2021-01-21 | JOHNSON WESLEY Director | Sale | -6,500 | -7.70%77,911 | $18.53 | $120,445 | View SEC filing | |
| 2020-08-12 | Trowbridge Stephen A EVP and CFO | Purchase | +1,013 | +1.71%60,273 | $9.38 | $9,502 | View SEC filing | |
| 2020-08-03 | Clemmer James C President and CEO | Purchase | +40,000 | +13.19%343,319 | $8.26 | $330,400 | View SEC filing | |
| 2019-10-28 | Clemmer James C President and CEO | Purchase | +15,000 | +6.11%260,418 | $14.19 | $212,850 | View SEC filing | |
| 2019-07-18 | Gould Kevin J Director | Sale | -13,650 | -19.85%55,124 | $21.45 | $292,793 | View SEC filing |
1-25 of 277
